LIMNHealthcare · Biotechnology

LIMN Stock Forecast: Liminatus Pharma, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$5.16

−9.03% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap

$346.5M

Ticker Nerd rank

10 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

−26.3%

+4200.0%

YTD

+745.9%

+85.6%

From 52W high

−31.2%

From 52W low

+5112.1%

$0.10

$7.50

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

LIMN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Liminatus Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

10 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Value

Issuance

Revisions

Momentum

Volatility

Quality

Growth

Size (94): Smaller than most of the companies we track.

Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LIMN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LIMN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LIMN appears on the weeks it earns a place.

Estimates

LIMN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Liminatus Pharma, Inc. (LIMN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −12.0×
Price / sales: —
Price / book: −1398.2×
EV / EBITDA: −84.9×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: 104.0%
Return on assets: −95.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LIMN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
LIMNLiminatus Pharma, Inc.	$346.5M	10
NIKINiki Biosolutions, Inc.	$7.0M	12
KAPAKairos Pharma Ltd.	$6.9M	38
BOLTBolt Biotherapeutics, Inc.	$7.0M	73
ENSCEnsysce Biosciences, Inc.	$7.3M	41
XCURExicure, Inc.	$7.3M	46
CURXCuranex Pharmaceuticals, Inc.	$7.4M	5

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Liminatus Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LIMN news & analysis

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

GlobeNewsWire · 18 Aug 2026neutral

Liminatus Pharma, Inc. announced that its board of directors adopted resolutions approving a 1-for-50 reverse stock split of its common stock. The split was approved by stockholders at the Company's 2026 Annual Meeting of Stockholders held on August 3, 2026.

Why it matters — A 1-for-50 reverse stock split will consolidate the number of outstanding shares and correspondingly adjust the per-share price of LIMN common stock, a significant corporate action for shareholders to track.

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

GlobeNewsWire · 13 Aug 2026neutral

Liminatus Pharma announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel granted the Company additional time to demonstrate compliance with Nasdaq's minimum bid price requirement.

Why it matters — This update is relevant to LIMN watchers because it addresses the Company's continued Nasdaq listing status and its bid price compliance timeline.

FAQ

Frequently asked questions about LIMN stock

How does Ticker Nerd's model rank LIMN?

As at 22 Aug 2026, Liminatus Pharma, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

What is the LIMN stock forecast for 2030?

No analyst covering Liminatus Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LIMN are extrapolating price history, which says nothing about the business.

How has LIMN stock performed over the past year?

Liminatus Pharma, Inc. returned +85.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Liminatus Pharma, Inc. do?

Liminatus Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies with an emphasis on immuno-oncology approaches.

What is the latest news on LIMN?

The most recent item we track (GlobeNewsWire, 18 Aug 2026): "Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock". Liminatus Pharma, Inc. announced that its board of directors adopted resolutions approving a 1-for-50 reverse stock split of its common stock. The split was approved by stockholders at the Company's 2026 Annual Meeting of Stockholders held on August 3, 2026.

Company

About Liminatus Pharma, Inc.

Liminatus Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies with an emphasis on immuno-oncology approaches. The company concentrates on immune-modulating treatments designed to target tumors more precisely by harnessing the body’s own immune system. Liminatus Pharma’s lead work includes a Guanylyl Cyclase C (GCC)–targeted vaccine being evaluated in mid-stage clinical trials for colorectal, pancreatic, gastric, and esophageal cancers that express GCC, addressing tumor types with significant unmet medical need. Its programs are positioned within the broader biotechnology and healthcare sectors, contributing to the oncology treatment landscape through novel therapeutic platforms rather than traditional chemotherapies. Liminatus Pharma Inc. operates today as a specialized innovator in cancer drug development, engaging primarily in research, clinical testing, and related translational activities. Founded in 2020 and headquartered in Cerritos, California, the company plays a focused role in the market as an emerging developer of targeted immuno-oncology candidates.

CEO Mr. Chris Kim J.D., L.L.M. · 1 employees · United States · https://liminatuspharma.com